Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VOLTAIRE-X: Pharmacokinetics, Safety, Immunogenicity and Efficacy of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: a Randomized, Double-blind, Parallel-arm, Multiple-dose, Active Comparator Trial

NCT03210259 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03210259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03210259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VOLTAIRE-X: Pharmacokinetics, Safety, Immunogenicity and Efficacy of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: a Randomized, Double-blind, Parallel-arm, Multiple-dose, Active Comparator Trial
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
July 10, 2017
Completion date
April 16, 2019
Enrollment
259 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis